标题:Engineered Thermoplasma acidophilum factor F3 mimics human aminopeptidase N (APN) as a target for anticancer drug development.
作者:Su J;Wang Q;Feng J;Zhang C;Zhu D;Wei T;Xu W;Gu L
作者机构:[Su, J] State Key Laboratory of Microbial Technology, Shandong University, Jinan 250100, China;[ Wang, Q] Department of Medicinal Chemistry, School of 更多
通讯作者:Xu, WF
通讯作者地址:[Xu, WF]Shandong Univ, Sch Pharm, Dept Med Chem, Jinan 250012, Peoples R China.
来源:Bioorganic and medicinal chemistry
出版年:2011
卷:19
期:9
页码:2991-2996
DOI:10.1016/j.bmc.2011.03.028
关键词:Aminopeptidase N; Inhibitors; Tricorn interacting factor F3; Crystal; structure; Drug design
摘要:Human aminopeptidase N (hAPN) is an appealing objective for the development of anti-cancer agents. The absence of mammalian APN experimental structure negatively impinges upon the progression of structure-based drug design. Tricorn interacting factor F3 (factor F3) from Thermoplasma acidophilum shares 33% sequence identity with hAPN. Engineered factor F3 with two point directed mutations resulted in a protein with an active site identical to hAPN. In the present work, the engineered factor F3 has been co-crystallized with compound D24, a potent APN inhibitor introduced by our lab. Such a holo-form experimental structure helpfully insinuates a more bulky pocket than Bestatin-bound Escherichia coli APN. This evidence discloses that compound D24 targetting the structure of E. coli APN cannot bind to the activity cleft of factor F3 with high affinity. Thus, there is a potential risk of inefficiency to design hAPN targeting drug while using E. coli APN as the target model. We do propose here now that engineered factor F3 can be employed as a reasonable alternative of hAPN for drug design and development.
收录类别:SCOPUS;SCIE
WOS核心被引频次:5
Scopus被引频次:5
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955467330&doi=10.1016%2fj.bmc.2011.03.028&partnerID=40&md5=e4a85a80f82cc16504a49c20d4f72a13
TOP